Negative / Null Result ReportOpen accessMedicine· cited by 37

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Stefan D. Anker; Javed Butler; Muhammad Usman; Gerasimos Filippatos; João Pedro Ferreira; Edimar Alcides Bocchi; Michael Böhm; Hans‐Peter Brunner‐La Rocca · 2022 · Nature Medicine

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract The EMPEROR-Preserved trial showed that the sodium–glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) ( n = 4,005; 66.9%) or mid-range (41–49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus plac

Abstract by Stefan D. Anker; Javed Butler; Muhammad Usman; Gerasimos Filippatos; João Pedro Ferreira; Edimar Alcides Bocchi; Michael Böhm; Hans‐Peter Brunner‐La Rocca, Nature Medicine (2022) — licensed CC BY 4.0.

Read the full paper (open access)